Thalidomide and the immune system. 4. Down-regulation of the CD26 receptor, probably involved in the binding of HIV components to T cells in primates.
Thalidomide (Thd) is capable of down-regulating the CD26 receptor on CD4+ lymphocytes after treatment of healthy volunteers. Similar effects are observed when marmosets (Callithrix jacchus) are treated with Thd. The Ta1 epitope of the CD26 receptor has recently been shown to bind the HIV-1 Tat trans-activating protein, and CD26 has also been suggested to be a coreceptor for the binding of the V3 loop of the gp120 HIV envelope protein. This might provide a hint for possible therapeutic interventions.
Neubert
R
R
University Medical Center, Free University Berlin, Germany.
Helge
H
H
Neubert
D
D
D000818:Animals; D000911:Antibodies, Monoclonal; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D002144:Callithrix; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects*; D015536:Down-Regulation / Q000187:drug effects; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D015728:Receptors, HIV / Q000187:drug effects*; D012016:Reference Values; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D013792:Thalidomide / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D015728:Receptors, HIV; D013792:Thalidomide; D018819:Dipeptidyl Peptidase 4